Rovin Brad H, Klein Jon B
Nephrology Division, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Nephrology Division, The University of Louisville School of Medicine, Robley Rex VA Medical Center, Louisville, KY, United States.
Clin Immunol. 2015 Nov;161(1):23-30. doi: 10.1016/j.clim.2015.04.021. Epub 2015 May 13.
Proteomics has long been considered an ideal platform, and urine an ideal source for biomarker discovery in human autoimmune kidney diseases. A number of studies have examined the urine proteome to identify biomarkers of disease activity, kidney pathology, and response to therapy. Increasingly, proteomic studies of kidney disease have expanded to include blood, circulating cells and kidney tissue. Recently the clinical potential of renal proteomics has been realized through a handful of investigations whose results appear to be applicable to patient care. In this review, approaches to the proteomic evaluation of autoimmune kidney diseases will be considered in the context of developing clinically useful disease biomarkers.
长期以来，蛋白质组学一直被视为一个理想的平台，而尿液则是发现人类自身免疫性肾脏疾病生物标志物的理想来源。许多研究已对尿液蛋白质组进行检测，以识别疾病活动、肾脏病理及治疗反应的生物标志物。对肾脏疾病的蛋白质组学研究越来越多地扩展到血液、循环细胞和肾脏组织。最近，通过一些研究已认识到肾脏蛋白质组学的临床潜力，其结果似乎可应用于患者护理。在本综述中，将在开发具有临床实用性的疾病生物标志物的背景下，探讨自身免疫性肾脏疾病蛋白质组学评估方法。
